(MENAFN- Trend News Agency) Chairman of the Board of Directors of Roche Holding AG Dr.
Christoph Franz arrived on a working visit to Kazakhstan. The Swiss
company plans to launch an enterprise for contract manufacturing of
anticancer drugs in Kazakhstan, the press service of KAZAKH INVEST
reports, trend reports citing kazinform .
On November 29, 2021, as part of the visit of the Head of State
Kassym-Jomart Tokayev to Switzerland, a Framework Agreement was
signed between the Ministry of health of the Republic of Kazakhstan
and Roche Holding AG. The agreement provided for the possibility of
increasing the local production of medical drugs through the
localization of production of innovative original drugs for the
treatment of oncological diseases. If this project is implemented,
patients will have access to innovative medicines and treatment
methods. In particular, this will be relevant for the treatment of
oncological diseases, such as breast cancer.
During this year, the parties agreed on approaches to further
improve the legislation in terms of stimulating technology
transfer, finding a local partner for further localization of
production, etc.
As part of the visit of Roche Holding executives to Kazakhstan,
an agreement was signed with the Ministry of Health on the
implementation of the project, securing the obligations of the
parties and ensuring the start of production, as well as the
production of the first Kazakhstan package of drugs by the end of
2023.
In addition, the Swiss company plans to create and launch an
«Innovative Training Center for Laboratory Diagnostics» at the
Nazarbayev University School of Medicine in 2023. The training
center will assist in improving the skills of local specialists in
terms of innovative diagnostic methods.
According to the Managing Director of KAZAKH INVEST Azamat
Kozhanov, a special subdivision of Task Force is aimed at
attracting large TNCs to work in Kazakhstan.
«Currently, our team is leading two large projects by SVEVIND
and Fortesque in the field of green hydrogen production. In
addition, work is underway to agree on the conditions for several
more projects under the Investment Agreement. The other day in
France, during the visit of the Head of State, a document was
signed with the French company Alstom. The general list consists of
70 projects with investments of more than $13 billion,» Azamat
Kozhanov stressed.
«The pharmaceutical industry is strategically important for our
country. In the context of the pandemic, we had to reconsider our
approaches to the development of the pharmaceutical industry. Thus,
the Government expects to increase the share of its own
pharmaceutical production in the country to 50% by 2025. The
arrival of the largest pharmaceutical company in the world, the
so-called «Big Pharma», is a landmark event for the development of
the industry as a whole. We are confident that the implementation
of the project will give a new impetus and bring the pharmaceutical
industry of Kazakhstan to a qualitatively new level. It is
important to note that Kazakhstan is one of the few countries that
have received the opportunity to develop contract manufacturing of
medicines. The company plans to further expand the pharmaceutical
production chain in the country,» said Almat Zhumabayev, project
manager at Investment Task Force KAZAKH INVEST.
The implementation of this project, implemented with the full
support of the Task Force division of «NC»KAZAKH INVEST«JSC, will
help to detect oncological diseases in patients at an early stage
and will greatly facilitate access to modern medicines for the
treatment of these diseases.